HLA-A and cervical cancer: To confirm the cervical cancer cell cytotoxicity of PBMCs sensitized E781–95 (#21) and E789–103 (#23) peptides, PBMCs from four HLA-A*02:01, A*24:02 donors were sensitized with E781–95 (#21) and E789–103 (#23) peptides in vitro for two weeks and were tested for cytotoxic effects on the HLA-matched cervical cancer cell line (HTB-34 restricted to HLA-A*02:01 and SNU-1160 restricted to HLA-A*24:02).